FTIR Sputum Spectroscopy for Non-Invasive COPD Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring chronic obstructive pulmonary disease (COPD) lack sensitivity and invasiveness, failing to predict disease progression and flare-ups effectively, with existing tools not suitable for routine, near-patient use.
Innovation Solution
The use of Fourier Transform Infrared Spectroscopy (FTIR) and Variable Filter Infrared Spectroscopy (VFIR) to analyze sputum samples, comparing spectral profiles within specific wavenumber ranges to identify COPD progression and risk of exacerbations, providing a non-invasive and practical diagnostic method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bronchial/lung biopsies and bronchoalveolar lavage are used for COPD assessment, then diagnostic accuracy is improved, but invasiveness increases and routine clinical use becomes difficult
Solution Approach 1:
The patent replaces invasive mechanical procedures (biopsies, lavage) with non-invasive optical spectroscopy (FTIR, Raman) to analyze sputum samples. This substitution maintains diagnostic accuracy by detecting biochemical changes in sputum components while eliminating the need for invasive lung tissue sampling, making the method suitable for routine clinical use.
Solution Approach 2:
The patent uses sputum as an intermediary substance that can be non-invasively collected and contains biochemical information about lung tissue. By analyzing sputum composition through spectroscopy, the method indirectly assesses lung tissue status without directly invading the lung, thus resolving the contradiction between diagnostic accuracy and ease of operation.
2Ease of operation
If exhaled breath analysis is used for COPD monitoring, then non-invasive monitoring is achieved, but sensitivity is reduced due to low levels of volatile organic compounds and nitric oxide
Solution Approach 1:
The patent uses sputum as a more concentrated intermediary medium compared to exhaled breath. Sputum contains higher concentrations of biochemical markers and cellular components, providing better sensitivity while remaining non-invasive. The spectroscopic analysis of sputum detects biochemical changes with higher sensitivity than volatile organic compound analysis in breath.
Solution Approach 2:
The patent changes the physical state and concentration parameters of the sample being analyzed. Instead of analyzing dilute gases in breath, the method analyzes concentrated biochemical components in sputum. This parameter change from gas phase to liquid/solid phase with higher concentration dramatically improves sensitivity while maintaining non-invasive collection methods.
3Ease of operation
If forced expiratory volume (FEV) measurements are used for COPD assessment, then routine measurement is simplified, but predictive capability for disease progression and flare-ups is lost
Solution Approach 1:
The patent replaces mechanical lung function testing (FEV measurements) with optical spectroscopy of sputum. This substitution provides biochemical information about inflammatory processes, tissue remodeling, and disease progression that FEV measurements cannot detect. The spectroscopic method maintains ease of operation while gaining predictive capability through detection of biochemical markers.
Solution Approach 2:
The patent uses sputum biochemical composition as an intermediary that contains predictive information about disease progression. The spectral analysis of sputum detects changes in protein, lipid, and carbohydrate content that correlate with disease severity and flare-up risk, providing predictive capability that simple volumetric measurements cannot offer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively identifies COPD progression and the risk of flare-ups at an early stage, enabling appropriate treatment and monitoring, with statistically significant differences in absorbance patterns between COPD and normal spectra, facilitating timely intervention.
Implementation Method 1
Fourier transform infrared spectroscopy (FTIR) is a non-invasive technology that can detect structural changes in molecules from tissue or cells. Such changes can be visualized using a spectrum of wave numbers usually taken from the mid infrared range (4000 to 400 cm−1).
Implementation Method 2
Spectroscopy methods such as FTIR and variable filter infrared spectroscopy (VFIR) can be used.
Data Source
AI summary
A method and kit are provided for diagnosing and monitoring the progress of COPD using FTIR spectral analysis of sputum samples where spectral data is obtained and used to monitor the progression of the disease over time.